



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

9 September 2024  
EMA/CHMP/QWP/708282/2018 Corr.1\*  
Committee for Medicinal Products for Human Use (CHMP)

## Guideline on quality and equivalence of locally applied, locally acting cutaneous products

Draft Agreed by QWP	7 June 2018
Adoption by CHMP for release for consultation	18 October 2018
Start of public consultation	14 December 2018
End of consultation (deadline for comments)	30 June 2019
Agreed by QWP	24 May 2024
Adopted by CHMP	9 September 2024
Date for coming into effect	2 April 2025

Annexes I and II of this guideline replace Annex 1 of the Guideline on Quality of Transdermal Patches (EMA/CHMP/QWP/608924/2014).

The guideline replaces Questions and Answer on Guideline: Clinical Investigation of Corticosteroids Intended for Use on The Skin CHMP/EWP/21441/2006.

<b>Keywords</b>	<b><i>Medicinal products for cutaneous use, topical products, locally applied locally acting medicinal products, skin permeation, in vitro release, stratum corneum sampling, tape stripping.</i></b>
-----------------	---

\*Page 18 - Section 5.2.1 has been corrected to read "(see Decision tree 1)"

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands  
**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)  
**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



# Guideline on quality and equivalence of locally applied, locally acting cutaneous products

## Contents

<b>Executive summary .....</b>	<b>4</b>
<b>1. Introduction and Background .....</b>	<b>4</b>
<b>2. Scope.....</b>	<b>5</b>
<b>3. Legal basis .....</b>	<b>6</b>
<b>4. Quality of Cutaneous Products .....</b>	<b>6</b>
4.1. Description and composition of the drug product .....	6
4.2. Pharmaceutical development .....	7
4.2.1 <i>Therapeutic objectives and product design</i> .....	7
4.2.2 <i>Active substance (P.2.1.1)</i> .....	7
4.2.3 <i>Excipients (P.2.1.2)</i> .....	7
4.2.4 <i>Formulation development (P.2.2.1)</i> .....	8
4.2.5 <i>Product characterisation</i> .....	9
4.2.6 <i>Administration</i> .....	11
4.2.7 <i>Manufacturing process development and Manufacture (P.2.3 and P.3)</i> .....	11
4.2.8 <i>Container closure system (P.2.4)</i> .....	12
4.2.9 <i>Microbiological Attributes (P.2.5)</i> .....	12
4.3 Control strategy .....	13
4.3.1 <i>Drug product specification (P.5)</i> .....	13
4.4 Stability program (P.8) .....	13
<b>5. Therapeutic equivalence of Cutaneous Products.....</b>	<b>14</b>
5.1 Stepwise approach for demonstration of therapeutic equivalence .....	14
5.2 Step 1 – pharmaceutical equivalence studies .....	15
5.2.1 <i>Pharmaceutical equivalence acceptance criteria</i> .....	16
5.3 Step 2 – Permeation kinetic studies .....	18
5.3.1 <i>Methods</i> .....	19
5.3.2 <i>General Considerations on Study Design and Analysis</i> .....	20
5.4 Step 3 – Pharmacodynamic Studies .....	22
5.5 Equivalence with respect to safety .....	23
5.6 Product Specific Equivalence Protocols .....	23
5.6.1 <i>Strength Biowaiver</i> .....	24
<b>6. Post-authorisation changes .....</b>	<b>25</b>
<b>Annex I In vitro release test (IVRT) .....</b>	<b>26</b>
1. Scope and rationale for IVRT .....	26
2. Study design .....	26
3. Method validation.....	27
4. Presentation of data .....	27

<b>Annex II In vitro skin permeation test (IVPT) .....</b>	<b>29</b>
1. Scope and rationale for IVPT .....	29
2. Study design .....	29
3. Method validation.....	30
4. Presentation of data .....	30
<b>Annex III Stratum Corneum (S.C.) Sampling (Tape Stripping).....</b>	<b>32</b>
1. Introduction .....	32
2. Method development and optimisation .....	32
3. Study design .....	33
4. Method validation.....	35
5. Data analysis and metrics .....	35
<b>Annex IV Vasoconstriction assay for corticosteroids .....</b>	<b>37</b>
<b>References: .....</b>	<b>38</b>
List of documents .....	38

## Executive summary

The guideline relates to locally applied and locally acting medicinal products for cutaneous use (referred hereby as cutaneous products), but may be also relevant for other medicines e.g., preparations for auricular or ocular use, and locally acting vaginal products.

Specific guidance is provided:

1. On the quality of cutaneous products not covered by other guidelines or the relevant Pharmacopoeia standards.
2. On equivalence testing of cutaneous products *in lieu* of therapeutic equivalence studies with clinical endpoints.

Existing guidelines state that, for cutaneous products, changes in formulation, dosage form, method of administration or manufacturing process may significantly influence the efficacy and/or safety. Therapeutic equivalence studies with clinical endpoints are in principle necessary, but other models may be used or developed.

Guidance is provided on other models and studies that may be used to determine equivalence with respect to (i) quality, (ii) efficacy, and (iii) safety that taken together support a claim of therapeutic equivalence, when the method of administration is the same.

Guidance is provided on situations where therapeutic equivalence studies with clinical endpoints are expected.

Scope, limitations and acceptance criteria of this approach are described.

The guidance should be used to develop and justify product-specific equivalence protocols.

In addition, guidance is provided in the Annexes for the design of:

- *in vitro* release
- *in vitro* human skin permeation
- *in vivo* stratum corneum sampling (tape stripping)
- *in vivo* vasoconstriction assay for corticosteroids

The quality guidance applies to new marketing authorisation applications and post approval changes.

The equivalence guidance is applicable to certain cases of demonstration of therapeutic equivalence of a new cutaneous medicinal product with an existing cutaneous medicinal product.

## 1. Introduction and Background

The diversity of cutaneous products is very wide given the complex nature of skin, the range of conditions to be treated and the variety of patients and their needs.

The guideline cannot present a single procedure to address such diversity, instead general recommendations are provided in accordance with the characteristics of the specific medicinal product.

The guideline elaborates existing regulatory guidance and is informed by current scientific knowledge.

Guidance on the quality of cutaneous products, not covered by other general quality guidelines or relevant Pharmacopoeial standards, is provided.

The indication, target population and site of action need to be understood to enable informed choices with respect to pharmaceutical form, composition, and method of administration.

The principal function(s) of the drug product need to be understood. This may simply be administration of the active substance to the surface of the skin. In many cases, bioavailability is increased by including in the product formulation excipients that change the thermodynamic activity of the active substance, e.g. by solubilisation and supersaturation, that modify active substance diffusion, or disrupt the physiological barrier (penetration enhancers). Occlusion and the vehicle itself, e.g. moisturisers, emollients, and excipients that evaporate after application of the drug product, may influence the condition to be treated.

The product formulation should be developed using sound prior knowledge, established scientific rationale and evidence. The resultant quality characteristics should be determined from multiple batches representative of the product to be marketed.

Existing guidelines state that, for topical products, changes in formulation, dosage form, method of administration or manufacturing process may significantly influence the efficacy and/or safety. Therapeutic equivalence studies with clinical endpoints are in principle necessary, but other models may be used or developed.

This guideline provides further detail on how *in vitro* and *in vivo* models may substitute for clinical data for the purpose of establishing therapeutic equivalence in a stepwise approach.

## 2. Scope

The guideline applies to locally applied and locally acting medicinal products for cutaneous use. These principles may also be relevant for other topical medicines, e.g. preparations for auricular or ocular use, and locally acting products, to be applied to vaginal mucosa or nails.

Guidance is provided on the quality of cutaneous products, containing chemical active substance(s), not covered by other general quality guidelines and on equivalence testing of cutaneous products to support a claim of therapeutic equivalence with reference medicinal products, *in lieu* of therapeutic equivalence studies with clinical endpoints.

The quality guidance (section 4) applies to new marketing authorisation applications and post approval changes.

The equivalence guidance (section 5) is applicable to certain cases of demonstration of therapeutic equivalence of a new medicinal product with an existing medicinal product. The guidance is applicable also to post-approval changes when potential impact on quality, safety or efficacy is expected based on the outcome of a risk assessment. Furthermore, in the case of applications which rely on literature to demonstrate the safety and efficacy of the medicinal product, the relevance of the literature should be supported by equivalence bridging data to the product described in the literature.

The equivalence guidance (section 5) does not apply:

- To biological medicinal products, see guidelines on similar biological medicinal products.
- To herbal medicinal products.
- When equivalence with respect to efficacy is demonstrated by therapeutic equivalence clinical trials.
- When the pharmaceutical form of the test and reference products are not the same.

### 3. Legal basis

This guideline should be read in conjunction with Directive 2001/83/EC and relevant Pharmacopoeial monographs and Guidelines; refer to the Annexed list of documents.

This guideline applies mainly to Marketing Authorisation Applications for human medicinal products submitted in accordance with Directive 2001/83/EC as amended, under Art. 8(3) (full applications) and Art. 10(3) (hybrid applications). It may also be applicable to Marketing Authorisation Applications for human medicinal products submitted under Art.10b (fixed combination), Art.10a (well-established use applications) of the same Directive, and for extension and variation applications in accordance with Commission Regulations (EC) No 1084/2003 and 1085/2003.

*In vivo* human studies in the EU/EEA should be carried out in accordance with Clinical Trials Regulation (EU) No. 536/2014.

*In vivo* human studies conducted outside of the EU/EEA but intended for use in a Marketing Authorisation Application in the EU/EEA should be conducted to the standards set out in Annex I of the community code, Directive 2001/83/EC.

In vitro human skin permeation kinetic equivalence trials, which are pivotal to a Marketing Authorisation Application, should be carried out in line with general quality practices to ensure the reliability of the results. When determining the nature of the quality practices to be applied, provisions in GxP guidelines may be of relevance.

Companies may apply for CHMP and national Scientific Advice for specific queries not covered by existing guidelines.

### 4. Quality of Cutaneous Products

#### 4.1. Description and composition of the drug product

The drug product composition and excipient functions should be described in detail.

The names of excipients should be specific and distinct. The recommended international non-proprietary name (INN or INN modified (INN<sup>M</sup>)) accompanied by the salt if relevant, or the Ph. Eur., or their usual common name, or the chemical name should be provided, otherwise the proposed name should be justified.

The excipient name should include the grade, and if informative also brand (commercial) name, if required for consistent manufacturability and product quality.

It should be explicitly stated when an excipient contributes in a multifunctional way to the design and purpose of the drug product, e.g. propylene glycol acting as a humectant, penetration enhancer and solubiliser.

The applied dose, in terms of mass of active substance per unit area, based on the SmPC instructions for use, and maximum daily dose, should be stated.

The primary packaging and, if necessary, secondary packaging or other materials or components required for reasons of stability or administration, should be described.

## **4.2. Pharmaceutical development**

The pharmaceutical development component of the dossier should form a sound scientific basis for the cutaneous product for its intended use, providing a clear narrative of product development, and include all relevant data.

### ***4.2.1 Therapeutic objectives and product design***

The Quality Target Product Profile (QTPP) should identify the intended therapeutic objectives and purpose of the drug product and explain how these objectives are achieved by the product design.

A patient-focussed approach should consider: indication and disease state of skin; age appropriateness, patient acceptability, administration and usability, administration site; efficacy in terms of product strength and posology, solute status of the active substance, and bioavailability and/or penetration enhancement; hydration and emolliency; safety in terms of ingredient toxicity, impurities, microbial quality; and quality in terms of physical and chemical stability, critical quality attributes (CQA) and compliance with pharmacopoeial and regulatory requirements.

The local site of action should be identified: skin surface; skin interior (stratum corneum, epidermis or dermis); or subcutaneous, adjacent tissues below the skin (regional).

The means and permeation kinetics by which the active substance reaches the local site of action should be explained. As applicable, this should address administration, the solution state of the active substance, dissolution, release from the product and diffusion through the different layers of human skin.

The inclusion of excipients having influence on bioavailability and condition of the skin should be explained and justified. The choice of formulation, e.g. (type of) aqueous gel, cream, ointment, should be explained and justified.

The amount of product delivered should be sufficient to cover the duration of treatment as specified on the product label, with a goal to also minimize unnecessary waste.

If applicable, the proportionality of different strengths should be discussed.

Cross references to relevant non-clinical and clinical sections of the dossier should be provided, as appropriate.

### ***4.2.2 Active substance (P.2.1.1)***

Active substance physicochemical properties that are important for bioavailability, the formulation, manufacturability, performance and stability of the drug product should be identified and discussed. Such properties may include molecular weight, partition coefficient, melting point (boiling point if applicable), pKa, sensitivity to light, air or moisture, degradation pathway, solubility and pH effects, as well as particle size and polymorphism, if the active substance is present in the solid state in the drug product. Critical quality attributes (CQAs) should be identified and controlled in the drug substance specification.

### ***4.2.3 Excipients (P.2.1.2)***

Excipients used in cutaneous products often show batch and source variation e.g. homologue composition of hydrocarbon chains, the degree of unsaturation, molecular weight and /or viscosity, polymorphism. This in turn may lead to unforeseen variability in the product rheological properties,

microstructure/physical properties, crystallisation of the active substance or other ingredient, stability, or bioavailability.

Batch and source variation of excipients should be considered and addressed during development.

The choice and quantity of each excipient, and relevant CQAs, should be discussed and justified in relation to its function(s).

The grade of the excipient should be specified, when active substance bioavailability, product manufacturability and / or quality is altered if other grades are used.

CQAs of the excipients should be controlled in their specifications and their limits justified (P.4.).

Detailed information on those excipients which might have an influence on the active substance permeation and bioavailability, e.g. solubiliser, penetration enhancer, disruption of physiological barriers, should be provided, including their ability to provide their intended function and to perform throughout the intended drug product shelf life.

In the case of excipients presented as a mixture of compounds, details of the composition should be provided in qualitative and quantitative terms and characterised, including rheological properties if appropriate.

For novel excipients, full details should be provided as outlined in the Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product (EMA/CHMP/QWP/396951/2006), under the section novel excipients.

For excipients also used in cosmetics, data showing compliance with Regulation 1223/2009 on Cosmetic Products, would be supportive.

Processing aids should be identified and described.

Some excipients traditionally used in cutaneous products may cause irritation or sensitivity reactions and should if possible be avoided, or minimised if unavoidable, in the development of a new product. For reference, see the guideline on "Excipients in the label and package leaflet of medicinal products for human use".

#### **4.2.4 Formulation development (P.2.2.1)**

The development of the drug product should be described with respect to the defined QTPP, employing suitable tests to characterise and control CQAs, factors affecting ease of administration and duration of use, and product performance e.g. dissolution, *in vitro* drug release and if appropriate *in vitro* skin permeation. Evidence of the suitability of the test methods and acceptance criteria used to assess the product should be provided (see also Annexes I and II).

Well-established excipients in usual amounts should be employed and possible interactions affecting drug bioavailability and/or solubility characteristics should be considered and discussed.

The presentation of the active substance in the drug product e.g. as a solute or in a suspension, and the degree of saturation are CQAs, which should be justified in terms of product efficacy and safety, supported by evidence of how the target state is achieved during manufacture and maintained during storage.

The risks of precipitation / particle growth / change in crystal habit, or changes to other active substance characteristics likely to affect bioavailability, arising from changes in temperature and on storage should be assessed and appropriate tests included in the stability studies.



The delivery of the active substance to the site of action needs to be discussed. Solvents and permeation enhancers can be used to aid transport through the different layers of the skin. Ointments may function to occlude the skin and thus facilitate permeation. The concentration gradient of the active substance between the drug product and the site of action is a driving force for delivery and achieving a saturated status of the active substance in the drug product can therefore be crucial.

Patient acceptability and usability of the drug product should be considered e.g. ease of removal from the container and ease of administration, spreadability, which can be of importance for dose per surface area and feel (dry or greasy).

Where appropriate, the type of the pharmaceutical form should be identified e.g. hydrophobic ointment (hydrocarbon base, absorption base), water emulsifying ointment, hydrophilic ointment.

Product microstructure/physical properties, which may be complex for semisolid products, and mechanisms responsible for its formation during processing, should be understood e.g. in terms of excipient interactions, batch variation and scale-up, so that the manufacturing process can be optimised to give a consistent quality product.

Transformation of the cutaneous product upon administration should be discussed. Particularly in those cases where evaporation of volatile solvents and excipients, or other phenomena, are necessary for effective drug delivery to the site of action.

The clinical trial formulation and the batches used in the comparative studies should be described in detail. Any differences in formulation and manufacturing processes between pivotal clinical batches and the drug product to be marketed should be justified. Results from comparative pharmaceutical equivalence studies, *in vitro* studies or *in vivo* studies should be provided.

When the formulation composition is decided, up-scaling of the manufacturing process will start and the critical process parameters should be identified and controlled.

During this period, it is reasonable to expect that necessary adjustments will be made to reach and optimise full-scale production. These adjustments might be changes in composition, manufacturing processes, equipment or manufacturing site. In some cases, the potential impact of these adjustments on the functions of the drug product, e.g. with respect to bioavailability and usability, should be assessed.

Evidence of compliance with Ph. Eur. requirements for the cutaneous dosage form should be provided.

The relationship between the QTPP, CQAs and the drug product specification should be fully discussed.

Where the drug product vehicle contains a flammable material or accelerant (e.g. isopropyl alcohol, paraffin) appropriate warnings should be included in the product information (see also section 4.2.6 Administration). The flash point of flammable liquids should be determined in compliance with relevant ISO standards as applicable.

#### **4.2.5 Product characterisation**

A detailed product characterisation should be developed to facilitate life-cycle management and, where applicable, to support a claim of equivalence to original or reference medicinal products.

Characterisation data should be derived from a representative number of batches taking account of the likely variation seen with disperse systems compared with simple solutions, and should not be less than three batches.

For product characterisation, the number of samples should be representative, with at least 6 units per batch for each experiment, unless otherwise justified. Between batch variability e.g., due to batch size, date of manufacture and period of storage, should also be taken into account.

#### *Pharmaceutical Form*

The diverse cutaneous dosage forms include cutaneous solutions and suspensions, foams and sprays, shampoos, ointments (e.g., hydrocarbon-, water-absorption-, water-removable- and water-soluble bases), creams (e.g., oil in water or water in oil), gels (e.g., single-phase or emulgels), pastes, poultices, medicated plasters and cutaneous patches; the list is non-exhaustive.

The pharmaceutical form should be defined also in terms of the solution state of the active substance, disperse and immiscible phases, and dosage form type, and evidence should be provided in this respect. For example:

- Active substance in solution, single phase vehicle: e.g., cutaneous solution, single phase gel or ointment.
- Active substance in suspension, single phase: e.g., cutaneous suspension.
- Active substance in solution, two phase vehicle: e.g., o/w cream, active substance in solution in oily phase.
- Active substance in suspension, two phase vehicle: e.g., o/w cream, active substance insoluble in either phase in suspension.

For suspensions, additional characterisation in terms of active substance particle size distribution and polymorphic form, including photomicrographs, is required.

For immiscible phase formulations, additional characterisation in terms of globule size distribution and appearance, including photomicrographs, is required.

Particle size analysis by diverse methodologies should be employed, if possible, e.g., laser light diffraction, Raman chemical imaging, as well as microscopy.

#### *Appearance*

This should be characterised visually and with microphotography - particularly for dispersed systems.

#### *Microstructure / Physical Properties*

Evidence should be provided to characterise the microstructure/physical properties in terms of bulk physical CQAs that influence bioavailability, usability or indicate variability in the manufacturing process and product instability;

- e.g., for solutions and aqueous suspensions – pH, buffering capacity, viscosity, density, surface tension, osmolality.
- e.g., for semisolid formulations – pH, density, rheological behaviour, water activity, impact on hydration of the skin (super)saturation, solubilisation.

Methods to assess and compare occlusivity and hydration state should be described in detail and appropriately justified, in particular discussing the relationship with the therapeutic situation.

Non-Newtonian rheological behaviour should be characterised using an appropriate absolute rheometer and include:

- A flow curve of shear stress (or viscosity) versus shear rate, comprising multiple data points across the range of increasing and decreasing shear rates so that any linear portions of the up-

curves or down-curves are clearly identified. The resulting curves should be characterised if feasible, by fitting to (modified) power law equations so that numerical data can be produced.

- Yield stress and creep testing
- The linear viscoelastic response (storage and loss modulus vs. frequency).

Unless otherwise justified, rheograms should be provided and the product's behaviour classified according to shear and time effects e.g. pseudoplastic, dilatant, thixotropic, and characterised using appropriate metrics. For example: viscosities at specified shear rates across the rheograms (e.g.  $\eta_{100}$ ); plastic flow yield stress values; thixotropic relative area ( $S_R$ ); viscoelastic storage and loss moduli ( $G'$  and  $G''$ ), apparent viscosity, loss tangent ( $\tan \delta$ ).

Appropriate characterisation of rheological properties and texture properties (as required) may enable the identification or design of a simpler test to be used in the Finished Product Specification.

#### *Product Performance*

Appropriate tests to characterise product performance such as dissolution of suspensions and *in vitro* drug release (Annex I) should be developed. Formulations characteristics that may influence the skin condition to be treated should also be investigated, e.g., emolency, moisturising, drying out, evaporation of components from the formulation (evaporation rate). Product performance should be shown to be stable during storage. *In vitro* skin permeation (Annex II) testing may also be of value.

### **4.2.6 Administration**

The SmPC and product information should include instructions for use and any necessary warnings for the safe use of the drug product as indicated below.

Where relevant, transformation of the drug product on administration should be described.

The following should be considered:

- Site of administration;
- The necessity to avoid damaged or undamaged skin;
- The requirements for skin pre-treatment;
- Effect of exposure to environmental extremes of heat, cold, sunlight;
- Effect of normal human behaviour such as washing, showers, use of sun screens and moisturisers;
- Any necessary restrictions e.g. avoidance of occlusion;
- The practical suitability of any special storage conditions;
- Avoiding inadvertent use by children;

For drug products containing flammable material or accelerant, appropriate flammability safety warnings should be included.

### **4.2.7 Manufacturing process development and Manufacture (P.2.3 and P.3)**

For dispersed drug products, e.g. two-phase emulsions, changes in formulation or manufacturing process may influence the efficacy and/or safety of the product and are therefore important to

evaluate and control. The order of addition of different components to the formulation can be of importance as well as process parameters such as temperature and homogenisation conditions e.g. speed, duration and reduced pressure.

In a typical manufacturing process, the critical points are generally the formation of a two- or multi-phase system from one-phase systems and the point at which the active substance is added.

As the drug release rate, microstructure/physical properties and rheological profiles of the drug product may be susceptible to scale-up effects, it is particularly important that these properties are verified at the commercial scale.

Modules 3.2.P.3.3 and 3.2.P.3.4 should be sufficiently detailed and include both critical and non-critical process parameters and justified by reference to the manufacturing process development undertaken.

Hold times and storage conditions of different solutions and intermediate materials should be stated and justified, supported by appropriate stability studies and other relevant data.

Many intermediate cutaneous products exhibit shear thickening in the days following manufacture. The time between intermediate product manufacture and filling may need to be optimised.

The suitability of the container for intermediates, bulk product storage, and transportation (shipping) should also be discussed.

#### **4.2.8 Container closure system (P.2.4)**

The suitability of the container closure system (described in 3.2.P.7) should be discussed and justified. This should include the choice of materials, protection from moisture, oxygen and light where applicable, drug product compatibility, extractables and leachables, dosing, usability and safety.

Drug products having sterile requirements should be packaged in single-use containers unless otherwise justified.

Compliance with MDR (Medical Device Regulation) is expected, if applicable. If any device is co-packaged to facilitate e.g. the measuring or application of the product, the device should be CE-marked. Compatibility between the device and the medicinal product should be shown and if it is a measuring device, the dose accuracy should be demonstrated with the applied product.

#### **4.2.9 Microbiological Attributes (P.2.5)**

Microbiological aspects should be considered in the same manner as for other administration routes, bearing in mind that cutaneous products are sometimes applied to damaged skin. Reference should be made to Ph. Eur. 5.1.4., Microbiological quality of non-sterile pharmaceutical preparations.

If sterility of the drug product is required, e.g., if it is to be used on large open or deep wounds or on severely injured skin and for preparations for irrigation, reference is made to Ph. Eur. Dosage forms monographs.

For non-sterile drug products in multiple-use containers the need, or not, to include an antimicrobial preservative should be addressed and justified. The concentration used should be at the lowest feasible level. Reference should be made to Ph. Eur. 5.1.3., Efficacy of antimicrobial preservation and the excipient guideline (Guideline on Excipients in the dossier for application for marketing authorisation of a medicinal product). For multi-phase formulations, the solubility of the preservative in the different phases needs to be considered.

## 4.3 Control strategy

General regulatory guidance on the establishment and justification of a control strategy for the drug product is given in other relevant guidelines, including ICH Q8, Q9, and Q10. Attention should however be paid to the control of CQAs required for the control of drug release, e.g., the *in vitro* drug release / dissolution (and, if appropriate, *in vitro* skin permeation) or other parameter(s) (e.g. microscopy, DSC, rheology) if they are proven to be more discriminative with regard to controlling drug release.

If possible, pharmaceutical development should establish the link between product quality attributes and clinical efficacy or local availability at the site of action.

### 4.3.1 Drug product specification (P.5)

General guidance on the drug product specification is given in ICH Q6A, Q3B, Q3C, Q3D and M7 and the Ph. Eur. dosage form monographs.

The drug product specification should contain tests for the physical, chemical and microbiological quality, and product performance i.e. the relevant product characteristics (see 4.2.5 Product characterisation) are controlled.

Crystal formation is a quality deficiency likely to adversely influence efficacy. Syneresis, the extraction or expulsion of a liquid from a semisolid, is another deficiency. Uniformity of the finished product in the container should be considered to detect sedimentation phenomena.

For cutaneous products, the calculation of maximum daily dose (MDD) for limits for degradation products is not as straightforward as for solid oral preparations or injections. It is up to the applicant to provide a justification on the approach used to calculate the MDD; at least the following are expected to be taken into account: area to be treated, absorption kinetics, condition of the skin (intact, wounded, disease to be treated, age of the patient, etc), method of administration, worst case conditions of application (e.g. occlusive). The duration of treatment and amount required is usually more varied. The exposure levels from cutaneous products can usually be considered much less than from routes with systemic exposure. Deviations from standard calculations should be justified from a safety perspective.

Specific precautions in calculating acceptance limits for impurities should be made for cutaneous products applied to damaged skin or products containing penetration enhancers.

Limits for performance tests, i.e. dissolution, *in vitro* release test (IVRT), if included in the specification, should be justified by reference to clinical batches for which satisfactory efficacy and safety has been demonstrated.

Release and shelf life limits should normally be the same, unless the reasons for the differences are satisfactorily explained on quality grounds and justified. Justification should be based on clinical batches or batches used in the pharmaceutical equivalence study with the reference product. Tighter limits at release may need to be set, to ensure that the product will remain within specification(s) during the approved shelf life.

## 4.4 Stability program (P.8)

To assure quality and stable product characteristics throughout storage, the designated shelf life needs to be based on the product specifications, e.g., physical, chemical and microbiological stability, and *in vitro* release or other performance tests, as required.

The risk factors to product stability should be assessed, e.g., precipitation, particle growth, change in crystal habit, or other active substance characteristics likely to affect the thermodynamic activity, changes in emulsion characteristics. Where relevant, appropriate tests should be included in the drug product release and shelf-life specification.

Shear thickening and changes in the product microstructure are also risk factors that should be considered.

The stability programme should include stress testing to assess the effect of severe conditions on the drug product, e.g. temperature cycling for emulsions.

The stability study quality specification should include tests to monitor the suitability of the container closure system.

Requirements for special storage conditions, e.g. do not refrigerate, should be addressed.

An in-use stability programme should be undertaken. It is important that these tests have a reasonable length considering dosage regimen and package size. A reasonable in-use shelf-life should be proposed based on the duration of treatment and the product stability.

## 5. Therapeutic equivalence of Cutaneous Products

Therapeutic equivalence means that the efficacy and safety profile of the test and reference products is sufficiently comparable so that a clinically relevant difference between products can be reliably excluded. Demonstration of therapeutic equivalence between cutaneous products is based on a stepwise approach.

### 5.1 Stepwise approach for demonstration of therapeutic equivalence

This section addresses the stepwise approach for testing of simple and complex cutaneous products to support a claim of therapeutic equivalence with a reference medicinal products, *in lieu* of therapeutic equivalence studies with clinical endpoints. Aspects relating to quality, efficacy, and safety are discussed.

For the purpose of this guideline, simple formulations are formulations with a single-phase base (matrix or vehicle) in which the active substance is in solution or suspension, e.g., solutions and suspensions in single phase liquids, -gels, or -ointments, and, do not contain excipients that are intended to enhance drug permeation or are difficult to characterise (e.g. of biological origin).


For the purpose of this guideline, complex formulations are multiphase systems, which are difficult to characterise structurally (e.g. emulsions), or formulations with excipients that are difficult to characterise, and formulations containing excipients that are intended to enhance drug permeation.

Demonstration of therapeutic equivalence by the stepwise approach is applied as follows:

1. pharmaceutical equivalence only (step 1, section 5.2).
2. permeation kinetic studies (step 2, section 5.3)
3. studies with pharmacodynamic (PD) or clinical endpoints (step 3, section 5.4).

Three decision trees are provided below in this stepwise approach. The applicable decision tree in each of the scenarios described below is illustrated in Scheme 1.

**Scheme 1. Selection of decision tree in the stepwise approach**



For solutions with the same qualitative composition (Q1) and similar quantitative composition (Q2), equivalence can be concluded if similar physicochemical properties (Q3) are shown (see Decision tree no. 1).

If the product is not a solution at the time of administration, but it can be classified as a simple formulation, equivalence can be concluded if Q1, Q2 and Q3 is shown and the products exhibits equivalence in a suitable in vitro release test (IVRT) (see Decision tree no. 1).

However, if the IVRT is not able to show equivalence, therapeutic equivalence could be concluded if it is shown in a permeation kinetic study (see decision tree no. 2, section 5.3). This is because it is assumed that the in vitro release differences are over-discriminative and not clinically relevant, since they disappear when investigating the skin permeation (e.g., the permeation is the limiting factor for drug availability into the site of action and not the release from the formulation).

For both simple and complex formulations, step 3 (section 5.4) is required, if pharmaceutical equivalence and equivalent permeation kinetics cannot be demonstrated.

For products containing a narrow therapeutic index (NTI) drug, this stepwise approach is not applicable and therapeutic equivalence studies with clinical endpoints are in principle required for NTI drugs for products containing a narrow therapeutic index drug.

## **5.2 Step 1 – pharmaceutical equivalence studies**

Demonstration of pharmaceutical equivalence requires comparative quality data with the relevant reference medicinal product. The products should be fully characterised (see section 4.2.5 Product characterisation). For the comparison of quality characteristics reference is made to the "Reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development" (EMA/CHMP/138502/2017).

Pharmaceutical form, qualitative and quantitative composition, microstructure/physical properties, method of administration and product performance, e.g. dissolution, *in vitro* release test, where relevant, should be compared. For volatile solvent based cutaneous products, product transformation on administration should also be compared (evaporation rate, water activity).

Product quality equivalence should be undertaken on batches representative of the product to be marketed and the manufacturing process – i.e. batches at or near production scale. Alternatively, pilot scale batches, at least 1/10 production scale may be used for characterisation and comparative purposes, if there are no changes in the manufacturing process and equipment, however evidence should be provided that scale-up does not affect product quality.

It is acknowledged that there may be only a limited number of representative batches available at the time of submission, and at least three different batches of both the test and reference products should be compared.

For the demonstration of equivalence, the number of samples should be at least 12 units per batch for each experiment, unless otherwise statistically justified. In case of high variability, a larger sample size may be required.

Data are also required to show that the product characteristics remain equivalent throughout the designated shelf-life (e.g. by comparing test and reference batches early and close to the end of shelf life).

### **5.2.1 Pharmaceutical equivalence acceptance criteria**

In the context of this guideline pharmaceutical equivalence means that the products under comparison have the same qualitative (Q1) composition, similar quantitative (Q2) composition, and that physicochemical and structural characterisation (arrangement of the matter, Q3) is the same or at least sufficiently similar.

The pharmaceutical equivalence acceptance criteria between the test and comparator medicinal product refers to:

*a) Pharmaceutical form*

- The drug product should be the same pharmaceutical form, with the same solution state of the active substance in the same phase.

*b) Qualitative and Quantitative Composition (Q1 & Q2)*

- The active substance content, its salt form and its polymorphic form, if the active substance is in solid form, should be the same. Differences in the salt form and/ or polymorphic form could be acceptable if equivalence is demonstrated via the 3-step approach.
- In general, the excipients qualitative composition, including grade if necessary, and quantitative composition of excipients should be the same, although some exceptions are permitted.

In particular, excipients whose function is to influence the active substance solubility, thermodynamic activity or bioavailability and product performance (e.g., in vitro release, residence time, occlusivity) should be qualitatively the same.

The nominal quantitative composition of these excipients should be the same or differences not greater than  $\pm 5\%$ . For example, for an excipient present in the reference medicinal product at 2% w/w, the permitted range in the test product is 1.9 – 2.1% w/w.

- A permitted exception for a *qualitatively* different excipient may be acceptable for:
  - Excipients whose primary function is not related to product performance or administration, i.e. antioxidants, antimicrobial preservatives, colorants, fragrances and do not have any other functions or effect that influences the active substance solubility, thermodynamic



activity or bioavailability, product performance, local tolerance and/or safety (see section 5.5 Equivalence with respect to safety).

- Excipient paraffin homologues may be acceptable for excipients whose function relates to the vehicle or emolliency, and the difference between the paraffin homologues do not influence the active substance solubility, thermodynamic activity or bioavailability and product performance (moisturising effect should remain the same).
- For excipients where it is claimed that their function relates to the vehicle properties or emolliency, a quantitative difference of not greater than  $\pm 10\%$  might be acceptable if it is demonstrated with appropriate data that these excipients do not have any other functions or effect that influences the active substance solubility, thermodynamic activity or bioavailability and product performance (e.g. moisturising or occlusive effect).

c) *Physicochemical and structural characterisation (Q3)*


The applicant should define and justify the critical quality attributes (CQAs) that are reflective of the arrangement of the matter of the drug product and consequently need to be compared. Also, the applicant should justify attributes that are not reflective of the arrangement of the matter and need not to be compared. For quality attributes reference is made to section 4.2.5 on Product characterisation, yet that section cannot be considered as exhaustive. For each product an up-to-date evaluation of quality attributes should be provided. The acceptance criterion for the comparison of the physicochemical parameters that ensures that the arrangement of the matter (Q3) is the same or at least sufficiently similar should be:

- For quantitative quality physicochemical characteristics, the 90% confidence interval for the geometric mean ratio of the test and reference products should be contained within the acceptance criteria of  $\pm 10\%$ , assuming lognormal-distribution of data (i.e. 90.00-111.11%). In case the reference product variability is higher than 10%, the acceptance range might be widened up to 80.00 -125.00 % depending on the reference product variability, using scaled-average-equivalence according to  $[U, L] = \exp [\pm k \cdot s_R]$ , where U is the upper limit of the acceptance range, L is the lower limit of the acceptance range, k is the regulatory constant set to 1.056 and  $s_R$  is the standard deviation of the log-transformed values of the reference product parameters. The table in section 4 of Annex I gives examples of how different levels of variability lead to different acceptance limits using this methodology. Alternatively, for quantitative quality physicochemical characteristics not related to rate or strength, a Critical Quality Attribute (CQA)-range (based on the underlying distribution for the reference product) may be proposed, using the principle that all reference product batches on the market represent acceptable quality. For physicochemical CQAs, demonstrating similarity using the overlap of the test distribution with this reference range may be a more appropriate approach than using a mean with a fixed percentage variation as the range of acceptance. Prior to the use of this approach in a submission, it is recommended that scientific advice be obtained from a competent authority.
- Non-quantitative quality characteristics should be essentially the same.

In addition to the pharmaceutical equivalence requirements listed above, also the method of administration should be the same and administration devices should be similar and achieve the same dose on application. If applicable, when product transformation occurs following administration (for example foams), the test and reference medicinal product residues should be equivalent with respect to quality, i.e., in terms of pharmaceutical equivalence.

For solutions with the same qualitative composition (Q1) and similar quantitative composition (Q2), equivalence can be concluded if similar physicochemical properties (Q3) are shown (see Decision tree no. 1). If the product is not a solution at the time of administration, but it can be classified as a simple formulation, equivalence can be concluded if Q1, Q2 and Q3 is shown and the products exhibits equivalence in a suitable in vitro release test (IVRT) (see Decision tree no. 1).

**Decision tree 1 (same qualitative and quantitative composition and same physicochemical and structural characterisation).**



\* IVRT: in vitro release test, IVPT: in vitro permeation test, TS: tape stripping, PK: pharmacokinetics, PK BE: pharmacokinetic bioequivalence study, PD: pharmacodynamic.

If the objectives and purpose of the drug product is only administration of the active substance to the surface of the skin, then pharmaceutical equivalence, including in vitro drug release for simple formulations, and equivalence in method of administration should normally be sufficient.

In simple formulations that are Q1, Q2 and Q3, as explained in this section, and are not able to show similar IVRT or in complex formulations that are Q1, Q2, Q3 and exhibit a similar IVRT, therapeutic equivalence may be concluded if its permeation kinetic is shown to be equivalent (see Decision tree 1).


### 5.3 Step 2 – Permeation kinetic studies

In those cases where the products are Q1 and Q2 similar, but Q3 cannot be concluded as similar (e.g. due to the large variability in some of the physicochemical parameters), equivalence could still be concluded if it is demonstrated that the IVRT and the permeation kinetic are equivalent and it is justified that those Q3 differences have no different impact on the condition of the skin (hydration,

softness), see Decision tree 2. Both products should produce a similar occlusion, hydration of the skin, transepidermal water loss, and have no different effect on skin microflora, skin pH, skin desquamation, lipid structure, etc. This may require specific in vitro and/or in vivo studies on the condition of the skin. Otherwise, studies with PD or clinical endpoints are needed (step 3, section 5.4).

In those cases where the products have different Q1 or Q2, but are able to conclude similar Q3 by the use of alternative excipients or different amounts of the same excipients with equivalent function, equivalence could still be concluded if it is demonstrated that the IVRT and the permeation kinetic are equivalent. It should also be justified that those Q1 and/or Q2 differences have no different impact on the condition of the skin (hydration, softness), see Decision tree 2. Both products should produce a similar occlusion, hydration of the skin, transepidermal water loss, and have no different effect on skin microflora, skin pH, skin desquamation, lipid structure, etc. This may require specific in vitro and/or in vivo studies on the condition of the skin. Otherwise, studies with PD or clinical endpoints are needed (step 3, section 5.4).

**Decision tree 2 (In case of small differences in qualitative and quantitative composition and/or physicochemical and structural characterisation).**



\* IVRT: in vitro release test, IVPT: in vitro permeation test, TS: tape stripping, PK: pharmacokinetics, PK BE: pharmacokinetic bioequivalence study, PD: pharmacodynamic.

Equivalence studies with respect to permeation kinetic are *always* required if either of the formulation (test or reference):

- Includes excipients whose function is to enhance drug permeation;
- Includes complex excipients where different suppliers or grades may affect the in vivo performance or stability of the active substance;

If based on the permeation kinetic outcome conducted with any of the methods described above, equivalence cannot be demonstrated, studies with PD or clinical endpoints are needed (step 3, see details in section 5.4).

### 5.3.1 Methods

The following methods are considered suitable for equivalence testing, *in lieu* of a clinical therapeutic study:

### **Permeation Kinetics Studies**

- *In vitro* skin permeation (see Annex II for specific guidance)
- *In vivo* Stratum Corneum Sampling (Tape Stripping) (see Annex III for specific guidance)
- Pharmacokinetic bioequivalence (see Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1 for specific guidance).

These tests provide a means of measuring equivalence in active substance permeation kinetics of drug products applied to intact skin. *In vitro* skin permeation and Stratum Corneum sampling studies are not suitable models for products applied to mucosa (e.g., rectal, buccal, vaginal).

Pharmacokinetic bioequivalence studies in healthy subjects are recommended when the active substance has quantifiable systemic bioavailability. If the drug has no quantifiable systemic exposure, but diffuses through the skin to permit quantification in the receptor cell, *in vitro* skin permeation studies are preferred. Stratum Corneum Sampling (Tape Stripping) should be limited to those cases when the drug does not permeate through the skin but there is sufficient quantifiable drug diffusion across the stratum corneum. If there is no quantifiable drug concentration in the stratum corneum, studies with PD or clinical endpoints are needed (Step 3, section 5.4).

Other techniques evidencing the drug diffusion and content at the site of action, such as Microdialysis/open flow microperfusion and Confocal Raman spectroscopy are not currently sufficiently established to provide pivotal evidence but may be supportive. They could be considered as pivotal evidence if appropriately qualified as suitable method for equivalence testing. These new approaches should preferably be confirmed by a CHMP qualification opinion (please refer to Qualification of novel methodologies for drug development: guidance to applicants, EMA/CHMP/SAWP/72894/2008).

### **5.3.2 General Considerations on Study Design and Analysis**

#### ***Managing Variability***

The test conditions should be standardised to minimise the variability of all factors involved except those of the products being tested. Pilot studies are recommended to develop and optimise procedures.

Because the studies are single-dose, product application is a significant source of variability. The dose application procedure should be practical and carefully described, in accordance with the SmPC of the reference product, and strictly controlled, e.g., use of administration templates or aids by a single or limited number of trained personnel. The procedure should enable determination of the actual dose applied. The procedure should be validated.

The study duration should be sufficient to permit quantitative observation of diffusion, but optimally limited to minimise changes in test conditions that may naturally occur, which introduce bias to kinetic profiles, e.g. desquamation, loss in skin integrity, back diffusion, accidental loss or transfer of applied dose.

The methods involve multiple complex steps. The studies should be conducted following strict protocols.

*In vitro* skin permeation and stratum corneum sampling (tape stripping) studies should include control formulations that are different and not equivalent to the test and reference products.

Inter-subject or inter-donor skin variability should be minimised by a cross-over study design.

For *in vitro* skin permeation and stratum corneum sampling (tape stripping) studies, the test, reference and control formulations should each be tested on the same set of volunteers or donor skin.

For low strength and limited diffusion drug products, the very low active substance concentrations expected in samples may be a significant source of variability. Sensitive analytical methods should be used, e.g. coupled chromatography – mass spectroscopy systems.

The analytical methods should comply with the ICH M10 Guideline on bioanalytical method validation and study sample analysis.

#### *Dose*

The dose, in terms of (a) mass of active substance, (b) application area, and (c) mass or volume of drug product used, should be specified and based on the reference product SmPC instructions for use.

The application area should be at least sufficient to achieve quantifiable results. If necessary, the area may be greater than normally indicated, if without safety concerns.

For *in vivo* studies, the skin site should be justified.

#### *Sample sizes*

The number of healthy subjects should be based on an appropriate sample size calculation and not less than 12.

For *in vitro* skin permeation studies, the number of skin donors should not be less than 12, unless otherwise justified, with at least 2 replicates per donor. A larger number of replicates may be needed in case of high intra-donor variability.

For *in vitro* skin permeation and stratum corneum sampling (tape stripping) studies, a replicate design is required. The minimum number of experiments for each of the test, reference and control products should not be less than 24.

The number and frequency of sample time points, per subject or replicate, should be sufficient to characterise the active substance kinetic profile and determine equivalence parameters.

#### *Acceptance Criteria*

The acceptance criteria for equivalence parameters is that the 90% confidence interval for the ratio of geometric means of the test and reference products should be contained within the acceptance interval of 80.00- 125.00%, unless justified.

Wider acceptance criteria for the 90% confidence interval, to a maximum of 69.84 – 143.19, may be accepted in the case of high within-subject or within-donor variability, and if clinically justified. The procedure in the Guideline on Investigation of Bioequivalence, "Section 4.1.10 Highly variable drugs or drug products" should be followed.

#### *Batches to be tested*

The test product batches used in the permeation kinetic studies must be prepared in accordance with GMP regulations including Eudralex volume 4 and should be representative of the product to be marketed and the manufacturing process – i.e. batches at or near production scale. Alternatively, pilot scale batches, at least 1/10 production scale may be used, if there are no changes in the manufacturing process and equipment, however evidence should be provided that scale-up does not affect product quality.


#### *Accreditation*

It should be ensured that the performing laboratory is qualified to undertake the studies and that an effective quality system is in place.

## 5.4 Step 3 – Pharmacodynamic Studies

In those cases where the drug has a deep site of action (i.e. sites of action beyond the dermis, e.g., joints) and its plasma levels are measurable, a pharmacokinetic bioequivalence study may be used to conclude therapeutic equivalence even when the formulations are not Q1, Q2, Q3 or the IVRT is not able to show equivalence (see Decision trees no. 1, 2 and 3). This is because it is assumed that if systemic exposure is equivalent, the exposure and absorption through the skin is also similar.

### ***Decision tree 3 (different qualitative and quantitative composition and different physicochemical and structural characterisation).***



\* PK BE: pharmacokinetic bioequivalence study, PD: pharmacodynamic.

The studies for some specific types of products discussed below provide a means of measuring in active substance's pharmacodynamic activity of drug products applied to intact skin. For products indicated for the treatment of open wounds and ulcers, the general principles of this guideline may be applicable. However, since in vitro and in vivo permeation kinetic and pharmacodynamic studies may not be applicable or considered insufficiently predictive of clinical response, other types of studies (e.g. pharmacokinetic bioequivalence studies in patients) could address these situations.

Other techniques, such as psoriasis microplaque assay or Laser Speckle Contrast Imaging, are not currently sufficiently established as method for equivalence testing, but may be used supportively.

In case permeation kinetic data do not fulfil the acceptance criteria and where validated PD models are not available, it is generally recommended to reformulate the product in order to show equivalence in Step 1 or 2 (section 5.2 or 5.3).

### **Corticosteroids**

The vasoconstriction assay for corticosteroids is accepted for equivalence testing.

The study should comply with the methodology described in Annex IV.

### **Skin Antiseptics**

For antiseptics that are formulated as cutaneous solutions that are Q1 and Q2 and Q3 equivalent, no further studies would normally be required for demonstration of therapeutic equivalence. In other cases, studies with PD or clinical endpoints are needed to demonstrate therapeutic equivalence.

Skin antiseptics should comply with Ph. Eur. 5.1.11. *Determination of bactericidal, fungicidal or yeasticidal activity of antiseptic medicinal products*. However it is noted that just compliance with the Ph. Eur. is not sufficient to demonstrate equivalent efficacy and safety.

Where the method of administration is poorly defined or new then *in vivo* volunteer tests should be undertaken. In these studies, volunteer's indigenous flora are recovered before and after skin antiseptics, with justified criteria for microbial recovery log reduction.

For skin antiseptics for use prior to invasive procedures, a study in compliance with ASTM E1173 – 15 *Standard Test Method for Evaluation of Pre-operative, Pre-catheterization, or Pre-injection Skin Preparations* or an equivalent European methodology would be acceptable.

### **Antimicrobial drug products for treatment of skin infections**

*In vitro* skin infection and decolonisation equivalence studies, if satisfactorily validated, may be acceptable to provide an assurance of equivalence in efficacy, in conjunction with the other equivalence studies described above in this guideline (5.1 stepwise approach).

## **5.5 Equivalence with respect to safety**

In general, safety and local tolerance may be guaranteed by knowledge of the active substance and the choice of well-established excipients.

Equivalence with respect to quality, when shown, provides an assurance of safety and local tolerance if the excipients are qualitatively the same and quantitatively similar. However, if the excipients are not qualitatively the same or not quantitatively similar, impact on the systemic and local safety profile should be addressed, including e.g., irritation, sensitisation, phototoxicity.

In addition, equivalence seen with permeation kinetic equivalence studies would show that the same amount of active substance is expected to reach the site of action and/or the systemic circulation as the reference medicinal product.

For cutaneous products, with a regional site of action, where the active substance has systemic bioavailability, bioequivalence studies provide evidence of both efficacy and safety.

For drugs with dose related, systemic toxicity, a bioequivalence study showing a similar systemic pharmacokinetic profile would be required to conclude that systemic exposure is not higher for the test product than for the reference product. Otherwise, clinical safety studies will be required.

## **5.6 Product Specific Equivalence Protocols**

The equivalence exercise should be performed and evaluated according to the step-wise approach as described above and based on a predefined study protocol including the selection of the reference product, the characteristics to be compared and equivalence tests, methods of comparison and acceptance criteria established for the specific product concerned together with proper justifications. The protocol should be prepared before commencing the equivalence studies. All data available, positive and negative, should be provided.

The choice of equivalence tests should consider the following key factors: method of administration, pharmaceutical form, product formulation, emolliency, skin hydration, drug dissolution and release,

and drug diffusion in the skin and site of action. For certain types of products, e.g. skin antiseptics, additional factors should also be considered, if applicable, for example microbiological quality, type of applicator, skin area (sebaceous-poor versus sebaceous-rich) and single versus multi-use container.

Equivalence may be concluded if results comply with the protocol criteria specified *a priori*.

In general, the product-specific equivalence protocol should comprise:

- Justification for the absence of a clinical therapeutic equivalence study; that the drug product is within and not out of the scope of this guideline (Section 5.1).
- Justification for the absence of safety studies (5.5 Equivalence with respect to safety).
- Pharmaceutical equivalence studies and equivalence in the method of administration (5.2 Step 1 – pharmaceutical equivalence studies).
- An appropriate skin permeation kinetic equivalence study, if diffusion through the skin is relevant to efficacy (Section 5.3.3) and justification of the choice of study or studies. Alternatively, if applicable, justification for the absence of kinetic equivalence studies.
- Pharmacodynamic studies should be performed, if appropriately validated and related with the therapeutic situation when equivalence cannot be shown in step 1 or 2 of the stepwise approach (section 5.2 or 5.3). The development, validation and conduct of novel studies is encouraged.

### **5.6.1 Strength Biowaiver**

For simple formulations, whose equivalence is demonstrated based on pharmaceutical equivalence, which also includes IVRT, each strength of the test product should be compared with the corresponding strength of the reference product.

For complex formulations, whose equivalence is demonstrated based on pharmaceutical equivalence including IVRT and in addition on permeation kinetic studies (5.3 Step 2 – Permeation kinetic studies), it may be sufficient to establish equivalence at only one strength, which is most sensitive to detect potential differences between formulations.

The following requirements must all be met where a waiver permeation kinetic studies for additional strength(s) is claimed:

- a) the different strengths of the test products are manufactured by the same manufacturing process.
- b) the different strengths of the test products have the same qualitative composition.
- c) the quantitative compositions of the different strengths of the test products are equivalent to the different strengths of the reference medicinal products. If they deviate, differences in quantitative composition between the strength used in the permeation kinetic study and other strengths of the test product, should be in line with the quantitative differences between the corresponding reference product strengths.
- d) for all strengths, similar physicochemical properties and IVRT (5.2 Step 1 – pharmaceutical equivalence studies) are demonstrated between the test and the corresponding strength of the reference medicinal product.



## 6. Post-authorisation changes

For any proposed change, a risk assessment should be performed to determine its impact on quality, safety, or efficacy of the product.

Risks arising from accumulation of changes from the original drug product should also be considered.

If the result of the risk assessment has a potential impact on quality, safety, or efficacy equivalence should be confirmed by comparison with the adequate reference product in line with section 5 of this guideline. The comparator for use in equivalence studies is usually that authorised under the currently registered formulation, manufacturing process, packaging, etc. In case of *ex vivo* or *in vivo* studies the comparator should be the reference medicinal product.

The following changes are some examples that are considered to have a potential significant impact on the safety, quality or efficacy of the drug product:

- A change in the physicochemical state and / or thermodynamic activity of the active substance;
- A change that affects dissolution, *in vitro* release, and/or *in vitro* permeation kinetic characteristics of the drug product.
- A change that affects occlusivity, emolliency, and/or skin hydration.
- A change in the manufacturing process, e.g. a change in a critical process parameter.

In all cases, the change should be supported by appropriate and representative batch data of the original and proposed change of all CQAs.

# Annex I In vitro release test (IVRT)

## 1. Scope and rationale for IVRT

This annex provides information for *in vitro* release test (IVRT) of semisolid drug products (e.g. creams, gels or ointments) and liquid suspensions.

An IVRT with pseudo-infinite dosing using diffusion cells evaluates the rate and extent of release of an active substance in the proposed formulation. Other equipment may be used (e.g. immersion cells).

The following parameters should be determined:

- Drug release rate (R): The slope of the cumulative amount of active substance released versus the square root of time for the linear portion of the drug release profile. If a linear portion of the drug release profile cannot be obtained, the IVRT is not valid.
- The cumulative amount (A) of active substance released, usually expressed in mass units per surface area, at the last sampling time of the linear portion.
- Lag time (if present)

For details about control strategy refer to section 4.3.

## 2. Study design

A pilot IVRT study comparing the test and reference products is recommended to confirm the suitability of the chosen membrane and to validate the experimental conditions.

The experimental conditions should be justified with respect to the following:

### a. Choice of membrane:

- i. The membrane should ensure that the product and the receptor medium remain separate to ensure the tested formulation remains unchanged throughout the testing period.

The membrane should not be rate-limiting to active substance release.

- ii. The membrane should be compatible with the drug product formulation and not bind to the active substance.

### b. Choice of receptor medium:

- i. Stability of the active substance in the receptor medium should be demonstrated.
- ii. Sink conditions should be confirmed. Sink conditions normally occur in a volume of medium that is at least 3-10 times the saturation volume. Importantly it should be demonstrated that linear (steady state) release rate for the duration of the study is achieved (also when the 150% of the strength of the test product is tested).
- iii. Back diffusion of the receptor medium should be minimised to avoid transformation of the applied drug product. In this regard the membrane pore size and where applicable the amount of small hydroxyl molecules should be justified. The pH of the receptor medium should remain constant throughout the release test.

- c. The sampling time (at least hourly) and experimental conditions (such as apparatus, temperature, mixing speed) should be defined. The duration of IVRT should be sufficient to characterise the release profile. At least 6 time points should be obtained covering the whole part of the linear

portion of the drug release profile, including the first sample immediately after drug diffusion has reached a steady state.

- d. The amount and method of formulation application should be described, consistent ( $\pm 10\%$  between samples) and validated to ensure homogeneous spreading of the formulation over the membrane and pseudo-infinite dose conditions. The effects of formulation evaporation should be minimised.
- e. The analytical methods should be sensitive enough to quantify the amount of drug in the receptor solution at various time points and validated.

### **3. Method validation**

The marketing authorisation application should include documented evidence that the IVRT has been validated and is suitable for the quality control of the drug product. A summary of the development of IVRT should be provided. Testing conditions providing suitable discrimination should be chosen.

- a. Satisfactory evidence of discrimination should be provided, with respect to both of the following quality modifications:
  - i. The release rate as a function of drug concentration (at least three strengths) in the formulation should be investigated. The linearity ( $r^2 \geq 0.90$ ) of the correlation of formulation concentration to rate of drug release (R) should be confirmed when the drug is fully dissolved. For suspensions, the relation between drug concentration and rate of drug release (R) should also be understood and discussed.
  - ii. Discriminative power of the proposed method should be demonstrated with altered product formulations with changes in CQAs (such as the active substance particle size distribution or drug product rheological profile), critical manufacturing variables and/or quantitative excipient composition; the complete omission of one or more specific excipients from the altered product formulation is not supported.

The suitability of the test conditions should be demonstrated by showing that the altered product formulations are statistically different and non-equivalent to the reference or to the to-be-marketed formulation.

- b. Intra-run and inter-run precision and reproducibility should be investigated.
- c. Method intermediate precision for the same batch should be studied with different operators on different days (CV < 10% preferably).
- d. Method robustness with respect to variations in mixing rate, amount of formulation applied and method of application, receptor mediums and temperature should be studied.

### **4. Presentation of data**

A minimum of 12 samples per batch should be used for initial method validation or to demonstrate equivalence. For routine release, a minimum of 6 samples would be accepted.

The *in vitro* drug release profile data should be provided in tabular and graphical formats.

For the drug release profiles, the quantity of active substance released in mass units per unit area at a given time should be reported.

For pharmaceutical equivalence testing:

- The cumulative amount of active substance released versus the square root of time should be linear.
- The parameter R should be significantly different from zero.
- The 90% confidence interval for the ratio of means of the test and reference products for the parameters (R) and (A) should be contained within the acceptance interval of 90.00 – 111.11%. In case the reference product variability is higher than 10%, the acceptance range might be widened up to 80.00 -125.00 % depending on the reference product variability, using scaled-average-equivalence according to  $[U, L] = \exp [\pm k \cdot s_R]$ , where U is the upper limit of the acceptance range, L is the lower limit of the acceptance range, k is the regulatory constant set to 1.056 and  $s_R$  is the standard deviation of the log-transformed values of the reference product parameters. The table below gives examples of how different levels of variability lead to different acceptance limits using this methodology.

CV(%)	Acceptance range	
10.00	90.00	111.11
12.50	87.68	114.06
15.00	85.42	117.06
17.50	83.24	120.14
20.00	81.13	123.27
21.365	80.00	125.00

- Lag times should normally be the same (i.e. within  $\pm 10\%$ ), if present.

## Annex II In vitro skin permeation test (IVPT)

### 1. Scope and rationale for IVPT

Establishing the characteristic permeation profile of the drug product, using a discriminative *in vitro* permeation test (IVPT) in skin, is of value in change control during life-cycle management and an acceptable permeation kinetic test to demonstrate therapeutic equivalence.

For therapeutic equivalence studies, test and reference products, together with a control that is shown to be statistically different and non-equivalent to the reference product, are compared.

### 2. Study design

To minimise risk of bias, the study protocol should specify methods of blinding and randomisation in line with ICH E8.

A pilot IVPT study comparing the test and reference products is recommended to confirm that the active substance permeates through the skin, to validate the experimental conditions (such as apparatus, dosing amount, sampling times, stirring rate, etc.) and may be of value in estimating sample size required for the pivotal IVPT study.

The experimental conditions should be justified with respect to the following:

a. Choice of skin membrane:

- i. Use of *ex vivo* animal skin is not currently sufficiently established to provide pivotal evidence. Therefore, *ex vivo* adult human skin should be used for therapeutic equivalence studies. The study protocol should specify the inclusion/exclusion criteria for skin sections, the anatomical region, condition and duration of skin storage. Skin with tattoos, any signs of dermatological abnormality or exhibiting a significant density of terminal hair should be excluded.
- ii. Different skin preparation techniques can be used. Evidence should be provided to demonstrate that the skin preparation technique and storage does not introduce artefacts, nor alter the skin barrier function. The use of full-thickness skin may artificially delay drug permeation and should be avoided unless otherwise justified. The skin thickness and separation technique should be described and justified.
- iii. The skin integrity should be checked prior to each experiment. The choice of the skin integrity test and its acceptance criteria should be explained. The proposed acceptance criteria should be justified and consistent across all parallel experiments.
- iv. Skin from different donors should be chosen. Test, reference and control formulations should be tested using the same donor skin, ideally from adjacent sites, per replicate.
- v. The number of skin donors should not be less than 12 unless otherwise justified, with at least 2 replicates per donor.
- vi. The apparatus should ensure consistent temperature control throughout the duration of the experiment. The skin surface temperature should be stable at  $32\pm1^{\circ}\text{C}$ .

b. Choice of receptor medium:

- i. Sink conditions should be confirmed as described with IVRT (Annex 1).

- ii. The receptor medium should be aqueous buffer, unless otherwise justified. Evidence should be provided that the chosen receptor medium does not compromise the skin barrier integrity throughout the test.
  - iii. The inclusion of an anti-microbial agent in the receptor medium, to mitigate potential bacterial decomposition of the skin membrane, and, if needed of a solubilisation agent, to ensure sink conditions of the test item in the receptor medium, is acceptable, but it should be demonstrated that they do not interfere with the properties of the skin or the assay.
- c. The number of sampling time points should be sufficient to obtain meaningful profiles, i.e. capturing the maximal rate of absorption and a decline in the rate of absorption thereafter, with more frequent sampling during the period of greatest change. The duration for testing should be 24 hours. If the study duration is longer than 24 hours, it should be shown that skin barrier function and integrity is adequately maintained.
  - d. The recommended dosing amount should be based on the SmPC posology, unless otherwise justified. Dose application should be validated to ensure reproducibility ( $\pm 5\%$ ) and homogeneous spreading of the formulation over the skin membrane. The donor compartment should be un-occluded unless otherwise specified in the SmPC.
  - e. To identify potential contamination and/or interferences, pre-dose samples collected from each diffusion cell and a parallel non-dosed blank control skin experiment are recommended.
  - f. A detailed description of the blinding procedure should be provided in the study protocol and final report. The packaging of the test, reference and control products should be similar in appearance to maintain adequate blinding. The method of randomization should be described in the protocol and the randomization schedule provided.
  - g. The analytical methods should be sensitive enough to quantify the amount of drug in the receptor solution at various time points and be appropriately validated.
  - h. The stability of the active substance in the receptor solution over the duration of IVPT study, and sample storage prior to analysis, should be confirmed.

### **3. Method validation**

The Marketing Authorisation Application should include documented evidence that the IVPT has been validated and is suitable for drug product comparison.

Discriminatory test conditions should be demonstrated using batches with different quality attributes that are shown to be statistically different and non-equivalent to the reference product.

To achieve this, batches with meaningful changes compared to the applied finished product should be manufactured. Such changes may relate to the quantitative formulation, CQAs and/or using slightly modified process parameters. Current knowledge of the characteristics derived from the active substance and the finished product formulation must be considered when choosing the quality attributes to change. The complete omission of one or more specific excipients from the formulation (e.g., penetration enhancer, preservatives) is not supported.

### **4. Presentation of data**

IVPT data should be provided in tabular and graphical formats. All individual data and parameters should be listed by formulation together with summary statistics. Both the plots of the cumulative amounts permeated per unit area (mass unit/cm<sup>2</sup>) as function of time and the plot of the rate of

absorption (mass unit/cm<sup>2</sup>/hr) as a function of time should be provided to characterise the release profile.

Relevant permeation parameters, e.g., the maximal rate of absorption ( $J_{\max}$ ) and total amount permeated per unit of area at the end of experiment ( $A_{\text{total}}$ ) should be determined and compared.

In the case of a replicate design, results obtained in the duplicate sites from the same donor should be averaged (geometric mean) prior to further analysis.

The acceptance criteria for equivalence parameters ( $J_{\max}$ ) and ( $A_{\text{total}}$ ) are:

- The 90% confidence interval for the ratio of means of the test and reference products should be contained within the acceptance interval of 80.00- 125.00%, unless justified.
- Wider 90% confidence interval limits, to a maximum of 69.84 – 143.19, may be accepted in the case of high variability observed with low strength and limited diffusion drug products, and if clinically justified. The procedure in the Guideline on Investigation of Bioequivalence, "Section 4.1.10 Highly variable drugs or drug products" should be followed.

In addition, for the test to be valid:

The acceptance criteria for equivalence parameters ( $J_{\max}$ ) and ( $A_{\text{total}}$ )

- The 90% confidence interval for the ratio of means of the test and *control* products should be entirely outside the interval of 80.00- 125.00%.
- The 90% confidence interval for the ratio of means of the reference and *control* products should be entirely outside the interval of 80.00- 125.00%.

Additional permeation parameters, such as the time of maximal rate of absorption ( $t_{\max}$ ) and lag-times, should also be reported. The lag-times between the test and reference products should be the same (i.e. within  $\pm 10\%$ ) if present. Any differences in the permeation parameters should be appropriately discussed with respect to equivalence.

The mass balance should be determined when possible. Depending on the type of products and its composition, a justification for not determining mass balance could be accepted. The cumulative amount of the active substance permeated into the receptor medium ( $A_{\text{total}}$ ), the total amount of active substance retained ( $S_{\text{total}}$ ) in the skin samples and amount of active substance retained on the cleaning or experimental equipment ( $R_{\text{total}}$ ) should be presented. The overall recovery of the active substance of 90-110% would be acceptable without justification, larger variation should be fully justified and explained.

The amount of active substance retained in different skin layers (such as the stratum corneum and epidermis) may be analysed separately to understand the active substance distribution in human skin.

# Annex III Stratum Corneum (S.C.) Sampling (Tape Stripping)

## 1. Introduction

This annex provides information for an *in vivo* stratum corneum sampling (or tape stripping (TS)) study for semi-solid formulations as a permeation kinetic method to show equivalence, *in lieu* of a therapeutic equivalence study.

The S.C. sampling study is a minimally invasive technique that involves sequential removal of the outermost skin layer (i.e., the stratum corneum (S.C.)) using adhesive tapes after application of a drug-containing formulation. The amount of drug in the S.C. depends on three main processes: drug partitioning from the formulation into the SC, drug diffusion across the S.C., and drug partitioning out of the S.C. into the viable tissues. A major advantage of TS is that the experiment is conducted *in vivo* with a fully functioning cutaneous microcirculation so that drug clearance from the skin is unimpeded.

TS data provide direct measurements and information on the local bioavailability of semi-solid drug products that act on or in the S.C. e.g. antifungal products. In cases when the target sites of action are beyond the S.C., TS data may provide a suitable surrogate to characterise the rate and extent of drug absorption to the underlying tissues.

*In vivo* TS studies are only applicable for products where drug diffusion into and through the SC takes place. Thus, TS should not be used for testing of drug products to be applied on significantly damaged skin (e.g. open wounds, burns) or skin of premature new-born. In addition, any products that contain volatile drugs or target primarily the cutaneous appendages (e.g. hair follicles, sebaceous glands) are also not suitable.

## 2. Method development and optimisation

A TS study is not an automated process and careful consideration of the experimental design is vital. The experimental conditions of the pivotal study should be assessed individually for the concerned products and should be established by performing a pilot TS study. A summary of the development and optimisation of the TS method should be provided.

The following experimental conditions should be established and verified during the pilot study:

- TS study should be conducted on healthy, normal e.g. forearm (volar) skin areas with adequate skin barrier function. The inclusion/exclusion criteria for skin conditions should be defined. Skin with tattoos, any signs of dermatological abnormality or exhibiting a significant density of terminal hair should be excluded. The preparation and cleaning procedures prior to the experiment should be established and further, that the treatment sites are not damaged by these processes.
- Skin integrity should be determined before the experiment. This is normally performed by the measurement of Transepidermal Water Loss (TEWL), although other techniques may be applicable if appropriate. The acceptance criteria should be fully discussed and justified.
- Due to inter-subject variability, the products to be compared should be applied on the same subject. Additionally, a control that is non-equivalent to the reference product should also be included to demonstrate the discriminatory power of the method. It is recommended to blind the investigator responsible for formulation application and tape stripping to minimise risk of bias.





- The dosing amount should be determined based on the SmPC. During the pilot study, the dosage and area of dose application should be verified to achieve a quantifiable mass of active substance in the SC. The dosing technique, blinding and randomisation procedures should also be established.
- A single dose approach should be followed, i.e. skin stripping is performed after a single application of the test and reference products.
- It is necessary that the products are compared at two time points (one uptake, one clearance) for each subject. The optimal uptake and clearance times depend on the characteristics of the drugs and products and should be determined during the pilot study. Ideally and when relevant, the uptake time should be sufficiently long for the drug to have attained the diffusional steady-state. This can be established by testing at multiple uptake times and from which time the mass of drug recovered from the SC remains constant. The clearance time should be long enough to allow measurable transfer of drug from the SC into the viable skin (and beyond) but should not exceed 48 hours to avoid any skin desquamation effect. The clearance time providing at least a 25% decrease in the mass of drug recovered from the SC with respect to that at the uptake phase is preferred. In all cases, the sampling times should be carefully considered and justified.
- The drug product should be removed from the skin surface after the specified uptake time. The cleaning procedure should be established to ensure that the residual formulation is efficiently removed from the treatment sites before stripping.
- The adhesive tape chosen should meet the following requirements: a) does not lose mass when applied and rubbed against the skin surface; b) minimal weight loss and gain during storage; c) the drug is readily extracted from the SC adhered to the tape; d) the adhesive or other components of the tape do not interfere with the analytical quantification of the drug; and e) the adhesive power should be such that the majority of the SC is removed with a sufficiently low number of tapes (e.g. not more than 30 tapes).
- The TS procedure followed must ensure that most of the SC ( $\geq 75\%$ ) is sampled for each skin site. The minimum and maximum number of tapes should be established based on the TEWL (or other relevant) criteria, e.g. eight-fold increment over baseline value, safety stop value.
- Most commonly, the drug is first extracted from the tapes then quantified in the extraction solvent(s). Alternative methods of extraction/quantification may be used if justified. Satisfactory efficiency should be demonstrated for the proposed extraction method.


### **3. Study design**

Detailed standard operating procedures should be prepared for the conduct of TS studies to ensure precise control of dosing, cleaning, stripping, extraction, quantification and other study variables or potential sources of experimental bias. The inclusion/exclusion criteria should be pre-defined and clearly stated in the protocol.


The following study design is recommended for TS studies. The final protocol developed for each specific case should be justified.



1) Drug is applied to the demarcated area and removed after the specified uptake time.



2) At the end of the uptake phase or after the specified clearance time, a template delineating the sample area is centered on the site.



3) Stripping begins using tapes that are larger than the sample area.

- Subjects – TS studies should be performed in healthy volunteers. The subjects should be screened for suitability in line with the principles of bioequivalence studies;
- Treatment area – healthy skin of the volar forearm areas sufficient to accommodate at least six application sites per forearm. Skin integrity should be verified e.g. by TEWL measurement. The same number of application sites should be assigned to each forearm;
- Number of subjects – the choice of the number of subjects should be justified based on the variability estimated from the pilot studies and demonstrated to be statistically relevant. A minimum of 12 subjects should be used to demonstrate equivalence;
- Number of replicates – at least two application sites per product (test, reference and a control) per forearm. One forearm should be used for uptake samples and the other for clearance;
- The products should be applied at pre-determined doses ( $\pm 5\%$ ) and spread evenly over the entire demarcated application sites. Blank samples should be collected from the adjacent areas to verify the absence of background levels of drug or other compounds that may interfere with the quantification of drug in the treated SC;
- The application sites should be randomised to avoid bias. The application time should be staggered to allow time for S.C. sampling;
- Un-occluded conditions, unless occlusion is recommended in the product information, or otherwise justified e.g. to prevent inadvertent removal of formulation;
- The formulation should be removed from all treatment sites (uptake and clearance) at the end of the uptake phase. The total cleaning time should be minimised to avoid any artefacts due to further drug diffusion. Skin integrity of the treated area should be checked before stripping;

- The 'uptake' sites should be tape-stripped immediately after formulation removal. The 'clearance' sites should be tape-stripped at the pre-defined clearance times;
- The exact number of tapes required should be determined based on TEWL measurements of the stripped area and the stopping criteria established from the pilot study;
- The mass of SC removed per tape should be determined using a gravimetric method by weighing the tapes strips before and after stripping. Alternative methods of quantification of the SC can be used if suitably described and justified;
- All stripped tapes collected from each treatment site should be analysed. The first two tapes should be analysed separately from the remaining tapes, so their contribution to the total amount of drug recovered can be evaluated. To enhance analytical detectability, the subsequent tapes can be combined in groups (e.g. each group containing the required minimum content of SC) for extraction. The total mass of drug in the SC should be calculated as the sum extracted from all tape strip samples. The mass balance, including the drug content removed from the surface by cleaning should be determined for each treatment site. The overall recovery of 90-110% would be acceptable without justification; larger variation should be fully explained.

#### **4. Method validation**

Cleaning the skin surface at the end of the application period prior to tape-stripping is important and must be capable of removing excess formulation (i.e. unabsorbed drug) efficiently without inadvertently 'driving' the drug into the barrier. The cleaning procedure usually involves quickly and gently wiping the skin with dry/wet tissue, cotton swabs and/or fresh alcohol wipes. The cleaning components should be known not to influence drug diffusion into and through the SC. A careful evaluation and validation of an efficient skin cleaning procedure should be performed prior to the pivotal study, e.g. by demonstrating satisfactory recovery (>90%) of the drug formulation removed from the skin surface and the negligible drug content (<10%) recovered by stripping the cleaned skin immediately after application. Other ways of validation may be used if suitably justified.

The bioanalytical method employed for drug quantification in the tape strips should be validated. The efficiency of the extraction procedures (including extraction of tape strips in groups) should be established and demonstrated as consistent prior to the pivotal study.

The discriminatory power of the TS method should be demonstrated for batches with different quality attributes (a control), such as a drug formulation, that is shown to be statistically different and non-equivalent to the test and reference products. The analytical methods for determining the content of active substance in the tape-stripped SC should be validated according to the Guideline on Bioanalytical Method Validation.

#### **5. Data analysis and metrics**

Data from all subjects should be reported and the validity and variability of the results should be discussed. All treated subjects and application sites should be included in the statistical analysis. The permitted reasons for exclusion must be pre-specified in the protocol. Data exclusion based on statistical analysis or for kinetic reasons alone is not acceptable.

For each product, the thickness of SC removed, the number of tapes used and final TEWL value measured at both uptake and clearance times should be reported. Any differences in these parameters between the test and reference products should be discussed with respect to equivalence.

A plot of drug content profile in the SC should be presented for each application site, e.g. the drug content of each SC tape strip (single or grouped) versus SC depth.

The duplicated measurements for each product in each subject should be averaged (population geometric mean) prior to analysis.

For the comparison of products, the equivalence parameters: mass of drug recovered from the uptake ( $M_{\text{uptake}}$ ) and clearance ( $M_{\text{clearance}}$ ) sites, should be statistically compared, according to the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr ).

The acceptance criteria for equivalence parameters ( $M_{\text{uptake}}$ ) and ( $M_{\text{clearance}}$ ) are:

- The 90% confidence interval for the ratio of means of the test and reference products should be contained within the acceptance interval of 80.00 - 125.00%, unless justified.
- Wider 90% confidence interval limits, to a maximum of 69.84 – 143.19, may be accepted in the case of high variability observed with low strength and limited diffusion drug products, and if clinically justified. The procedure in the Guideline on Investigation of Bioequivalence, "Section 4.1.10 Highly variable drugs or drug products" should be followed.

In addition, for the test to be valid:

The acceptance criteria for equivalence parameters ( $M_{\text{uptake}}$ ) and ( $M_{\text{clearance}}$ )

- The 90% confidence interval for the ratio of means of the test and *control* products should be entirely outside the interval of 80.00 - 125.00%.
- The 90% confidence interval for the ratio of means of the reference and *control* products should be entirely outside the interval of 80.00 - 125.00%.
- The 90% confidence interval for the ratio of means of the *test product* clearance ( $M_{\text{clearance}}$ ) and ( $M_{\text{uptake}}$ ) reference products should be entirely below 1.0.
- The 90% confidence interval for the ratio of means of the reference *product* clearance ( $M_{\text{clearance}}$ ) and ( $M_{\text{uptake}}$ ) reference products should be entirely below 1.0.

The overall conclusions of the study should be provided. This should be supported by a sound scientific discussion and interpretation of the TS data.

## **Annex IV Vasoconstriction assay for corticosteroids**

A description of the protocol for the assay should be provided.

The following testing principles should be followed:

An *in vivo* pilot dose duration-response study should be undertaken to determine the study requirements for determining the equivalence parameters to be used in the pivotal equivalence study.

Relevant human volunteer inclusion and exclusion criteria should be stated and adhered to for both pilot and pivotal studies.

Healthy subject with an adequate vasoconstriction to cutaneous corticosteroids must be included.

Test product, vehicle, reference product, and untreated control should be randomly assigned to application sites on the ventral forearms.

The study should be appropriately blinded.

For the pivotal study, a minimum of 12 subjects should be included.

The vasoconstriction reaction should be determined at baseline (before drug application), time of drug product removal, and several times after drug product removal (e.g. 2, 4, 6, 19, 24 hours).

The time course of response should be followed until return to baseline to ensure that maximal pharmacodynamic response is observed. The assay must be optimised to ensure that the products are compared in the linear portion of the blanching curve. Several application times should be tested in pre-test. The lower limit of sensitivity should be determined.

The vasoconstriction reaction should be determined at several time points and AUC data should be generated. A single time point for estimation of the vasoconstriction reaction is not acceptable.

The measurement of the vasoconstriction reaction should be performed by using a chromameter, or other methods more sensitive than visual estimation.

## References:

- 1 Topical Dermatologic Corticosteroids: In Vivo Bioequivalence Guidance for Industry, October 2023.
- 2 "Quantification of corticosteroid-induced skin vasoconstriction", *Dermatology*, (2002), 205, 3-10.
- 3 "The skin-blanching assay", *Journal of the European Academy of Dermatology and Venerology* (2012), 26, 1197-1202.

## List of documents

### **Quality Guidelines**

- European Pharmacopoeia (Ph. Eur.) Dosage Form Monographs: Liquid Preparations for Cutaneous Application; Powders for Cutaneous Application; Semi-Solid Preparations for Cutaneous Application; Ear Preparations; Eye Preparations; Pressurised Pharmaceutical Preparations, Vaginal preparations.
- Pharmaceutical Development, ICH Q8 (R2), EMEA/CHMP/167068/2004;
- Manufacture of the Finished Dosage Form, EMA/CHMP/QWP/245074/2015;
- Guideline on Process Validation for finished products. Information and data to be provided in Regulatory Submissions, EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1;
- Excipients in the Dossier for Application for Marketing Authorisation of a Medicinal Product, CHMP/QWP/396951/06;
- ICH Q 6A: Specifications: Test Procedures and Acceptance Criteria for New Active substances and New Drug Products: Chemical Substances, CPMP/ICH/ 367/96-ICH Q6A;
- ICH Q 2(R2): Validation of Analytical Procedures: Text and Methodology, EMA/CHMP/82072/2006 - ICH Q2 (R2);
- ICH Q1A (R2): Stability Testing of New Active substances and Drug Products, CPMP/ICH/2736/99-ICH Q1A (R2);
- Stability Testing of Existing Active Ingredients and Related Finished Products, CPMP/QWP/122/02 Rev. 1 corr.;
- ICH Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management, EMA/CHMP/ICH/804273/2017.

### **Other relevant Guidelines**

- Note for Guidance on the Clinical Requirements for Locally Applied, Locally Acting Products containing Known Constituents (CPMP/EWP/239/95 Final);
- Guideline on the Investigation of Bioequivalence, CPMP/EWP/QWP/1401/98 Rev. 1/ Corr;
- ICH M10 on bioanalytical method validation - EMA/CHMP/ICH/172948/2019;
- General Considerations for Clinical Trials, ICH topic E8, CPMP/ICH/291/95;
- Guideline for Good Clinical Practice (ICH E6 (R1), CPMP/ICH/135/95;
- Statistical Principles for Clinical Trials, ICH E9, CPMP/ICH/363/96;

- Reflection Paper on advice to Applicants / Sponsors/ CROs of Bioequivalence Studies, EMEA/INS/GCP/468975/2007;
- Reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development, EMA/CHMP/138502/2017;
- Qualification of novel methodologies for drug development: guidance to applicants, EMA/CHMP/SAWP/72894/2008.